New primary monoclonal antibodies · 19. September 2023
SYnabs monoclonal antibodies to metalloproteinases proMMP9 and activated MMP9 as diagnostic and therapeutic tools for immune diseases, neurological diseases and strokes
Secondary monoclonal antibodies · 15. June 2023
SYnAbs rat-LOU anti-mouse IgM to monitore immune primary isotypic response, in-vivo deplete B-cells & circulating IgM, and easily purify IgM isotype mouse monoclonal antibodies by immuno-affinity chromatography
New primary monoclonal antibodies · 24. April 2023
CRP is synthesized by the liver in response to several inflammatory cytokines and is a well-established biomarker of inflammation and infection. Elevated CRP levels are associated with several diseases, including inflammatory bowel disease, rheumatoid arthritis, cardiovascular disease, infection, and cancer. SYnAbs Monoclonal antibodies offer several advantages for CRP diagnosis in a precision medicine context.
Epigenetics and Monoclonal histone modification antibodies · 01. April 2023
How epigenetic alterations on histones are strong biomarkers of disease evolution and how to target these post-translational modifications effectively with SYnAbs higher specific mouse and rat monoclonal antibodies
New primary monoclonal antibodies · 11. February 2023
Thanks to unique technologies to break immune tolerance, SYnAbs generate monoclonal antibodies to Matrix metalloproteinases (MMPs), extracellular proteinase enzymes involved in the degradation of the extracellular matrix.
25. January 2023
SYnAbs generates R&D, surrogate and therapeutic monoclonal antibodies targeting occludin and claudin highly homologous transmembrane proteins
New primary monoclonal antibodies · 25. November 2022
Synabs announces a large Horizon European grant for the generation of therapeutic antibodies on transmembrane targets and highly conserved soluble proteins
Ion channel therapeutic monoclonal antibodies · 22. October 2022
SYnAbs' unique approach generating ultra-specific therapeutic monoclonals to ion channels and effectively treat channelopathies thanks to a unique antibody platform
New primary monoclonal antibodies · 03. October 2022
SYnAbs monoclonals specific to glucagon without cross-reaction to GLP-1, Glicentin, Oxyntomodulin and Proglucagon, to diagnose diabetes and glucagonomas diseases
GPCR therapeutic monoclonal antibodies · 20. September 2022
SYnAbs and Domain Therapeutics enter into a strategic partnership for the discovery and development of therapeutic antibodies targeting complex G Protein Coupled Receptor targets for immuno-oncology indications
SYnAbs S.A.
Rue Auguste Piccard, 48
I-Tech Incubator 2
B-6041 Gosselies
Belgium
+32 (0)71/374.880
BE 0637.716.206
